Kristina Ilieva Ivanova

Mrs. Kristina Ilieva Ivanova

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KNKalina Nikolova-Ganeva
Kalina Nikolova-Ganeva
NMNikolina Mihaylova
Nikolina Mihaylova
LKLidiya Kechidzhieva
Lidiya Kechidzhieva
KIKristina Ilieva Ivanova
Kristina Ilieva Ivanova
AZAlexander S. Zarkov
Alexander S. Zarkov
AMAndrey Marchev
Andrey Marchev
Rheumatoid arthritis (RA) is a progressive and systemic autoimmune disease, characterized by a chronic inflammatory process, affecting the lining of the synovial joints, many body organs/systems, and blood vessels. Its pathological hallmarks are hyperplasic synovium, bone erosion, and progressive joint destruction. Rheumatoid arthritis affects over 20 million people, with a worldwide prevalence of 0.5–1.0%, exhibiting gender, ethnic, and geographical differences. The progressive disability severely impairs physical motion and quality of life and is finally leading to a shortened life span. The pathogenesis of RA is a complex and still poorly understood process in which genetic and environmental factors are principally associated. Current treatment mostly relies on conventional/non-biological disease-modifying anti-rheumatic drugs (cDMARDs), analgesics, non-steroidal anti-inflammatory drugs, glucocorticoids, steroids, immunosuppresants, and biologic DMARDs, which only control inflammation and pain. Along with side effects (drug toxicity and intolerance), these anti-rheumatic drugs possess limited efficacy. Therefore, the discovery of novel multi-target therapeutics with an improved safety profile that function as inhibitors of RA-linked signaling systems are in high demand, and this is in the interest of both patients and clinicians. Plant-derived extracts, nutritional supplements, dietary medicine, and molecules with anti-inflammatory activity represent promising adjuvant agents or alternatives for RA therapeutics. This review not only aims to discuss the basic features of RA pathogenesis, risk factors, and signaling pathways but also highlights the research progress in pre-clinical RA in in vitro and in vivo models, revealing new avenues in the management of the disease in terms of comprehensive multidisciplinary strategies originating from medicinal plants and plant-derived molecules.

16 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KNKalina Nikolova-Ganeva
Kalina Nikolova-Ganeva
NMNikolina Mihaylova
Nikolina Mihaylova
LKLidiya Kechidzhieva
Lidiya Kechidzhieva
KIKristina Ilieva Ivanova
Kristina Ilieva Ivanova
AZAlexander S. Zarkov
Alexander S. Zarkov
AMAndrey Marchev
Andrey Marchev
Rheumatoid arthritis (RA) is a progressive and systemic autoimmune disease, characterized with a chronic inflammatory process, affecting the lining of the synovial joints, many body organs/systems and blood vessels. Its pathological hallmarks are hyperplasic synovium, bone erosion, and progressive join destruction. Rheumatoid arthritis affects over 20 million people with a worldwide prevalence of 0.5-1.0%, exhibiting gender, ethnic and geographical differences. The progressive disability severely impairs physical motion, quality of life, and is finally leading to a shortened life span. The pathogenesis of RA is a complex and still poorly understood process in which genetic and environment factors are principally associated. The current treatment mostly relies on conventional/non-biological disease modifying anti-rheumatic drugs (cDMARDs), analgesics, non-steroidal anti-inflammatory drugs, glucocorticoids, steroids, immunosuppresants and biologic DMARDs, which only control inflammation and pain. Along with the side effects (drug toxicity and intolerance), these anti-rheumatic drugs possess limited efficacy. Therefore, the discovery of novel multi-target therapeutics with no side effects that function as inhibitors of RA-linked signaling systems are in high demand and this is in interest in both, patients and clinicians. Plant-derived extracts, nutritional supplements, dietary medicine and molecules with anti-inflammatory activity represent promising adjuvant agents or alternatives for RA therapeutics. This review aims not only to discuss the basic features of RA pathogenesis, risk factors and signaling pathways, but highlights the research progress in pre-clinical RA in vitro and in vivo models revealing new avenues in management of the disease in terms of comprehensive multidisciplinary strategies originating from medicinal plants and plant-derived molecules.

Verified
Journal Article
Open access
PDF file
ABAina Bellver-Sanchis
Aina Bellver-Sanchis
NRNikola Ralchev Ralchev
Nikola Ralchev Ralchev
PRPatrizia Roman Romanska
Patrizia Roman Romanska
NDNikoleta Dyakova
Nikoleta Dyakova
KIKristina Ilieva Ivanova
Kristina Ilieva Ivanova
AMAndrey Marchev
Andrey Marchev
Alzheimer’s disease (AD) is a neurodegenerative disorder, which is characterized by several features, such as the deposition of amyloid β (Aβ) fibrils in the brain, leading to the formation of plaques and secondly tau-associated neurofibrillary tangles, resulting in the degeneration of the brain cells. Another feature of AD is mitochondrial dysfunction and oxidative stress, which are linked to the excessive production of reactive oxygen species (ROS). Under physiological conditions, ROS homeostasis is well controlled by the ROS generating system and the cellular antioxidant network. This antioxidant network is in part controlled by nuclear factor erythroid 2-related factor 2 (Nrf2), and its activation protects tissues against oxidative stress and chronic inflammation. Since oxidative stress, inflammation, and impaired proteostasis are significantly involved in the pathogenesis of AD, the KEAP1-Nrf2 system has emerged as a promising therapeutic target for the disease. Caenorhabditis elegans is an invaluable model organism among others for neurodegenerative disease research, due to its short life cycle, transparent body, and fully mapped nervous system and many transgenic C. elegans models have been developed to study different aspects of AD. This review attempts to provide comprehensive understanding of the molecular characteristics and pathological basis of AD, including the altered Nrf2-ARE signaling in AD and the molecular architecture and regulation of the Nrf2-SKN-1 pathway in C. elegans. An overview of plant-derived natural products and their effect on Nrf2/SKN-1 activation. Several classical and novel transgenic strains are described, translating findings from C. elegans to mammalian models and humans, including clinical translations and ongoing trials, as well as personalized medicinal approaches are discussed.

30 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ABAina Bellver-Sanchis
Aina Bellver-Sanchis
NRNikola Ralchev Ralchev
Nikola Ralchev Ralchev
PRPatrizia Roman Romanska
Patrizia Roman Romanska
NDNikoleta Dyakova
Nikoleta Dyakova
KIKristina Ilieva Ivanova
Kristina Ilieva Ivanova
AMAndrey Marchev
Andrey Marchev
Alzheimer’s disease (AD) is a neurodegenerative disorder, which is characterized by several features, such as the deposition of amyloid β (Aβ) fibrils in the brain, leading to the formation of plaques and secondly tau-associated neurofibrillary tangles, resulting in the degeneration of the brain cells. Another feature of AD is mitochondrial dysfunction and oxidative stress, which are linked to the excessive production of reactive oxygen species (ROS). Under physiological conditions, ROS homeostasis is well controlled by the ROS generating system and the cellular antioxidant network. This antioxidant network is in part controlled by nuclear factor erythroid 2-related factor 2 (Nrf2), and its activation protects tissues against oxidative stress and chronic inflammation. Since oxidative stress, inflammation, and impaired proteostasis are significantly involved in the pathogenesis of AD, the KEAP1-Nrf2 system has emerged as a promising thera-peutic target for the disease. Caenorhabditis elegans is an invaluable model organism among others for neurodegenerative disease research, due to its short life cycle, transparent body, and fully mapped nervous system and many transgenic C. elegans models have been developed to study different aspects of Alzheimer’s disease. This review at-tempts to provide comprehensive understanding of the molecular characteristics and pathological basis of AD, including the altered Nrf2-ARE signaling in AD and the mo-lecular architecture and regulation of Nrf2-SKN-1 pathway in C. elegans. An overview of plant-derived natural products and their effect on Nrf2/SKN-1 activation. Several classical and novel transgenic strains are described, translating findings from C. elegans to mammalian models and humans, including clinical translations and ongoing trials, as well as personalized medicinal approaches are discussed.